EXHIBIT 3 TO NUVASIVE, INC.'S NOTICE OF LODGMENT OF WITNESS DEPOSITION DESIGNATION CLIP REPORTS

NuVasive v. Alphatec - Video

Robinson, Scott (Vol. 01) - 10/29/2019

1 CLIP (RUNNING 00:13:10.424)



30 SEGMENTS (RUNNING 00:13:10.424) **SR-ALL FINAL**



1. PAGE 7:19 TO 7:24 (RUNNING 00:00:11.066)

- 19 Ο. Good morning, Mr. Robinson.
- Hello. 20 Α.
- 21 Q. Would you please state and spell your
- 22 name for the record.
- 23 Scott Robinson. S-c-o-t-t, Α.
- R-o-b-i-n-s-o-n.

2. PAGE 8:03 TO 8:06 (RUNNING 00:00:12.534)

- 0.3 Q. Who is your current employer?
- 04 Alphatec Spine. Α.
- 05 Q. How long have you been employed there?
- 06 Α. Since March of 2010; going on 10 years.

3. PAGE 26:08 TO 26:17 (RUNNING 00:00:22.423)

- Topic 2 is -- I'm just going to read
- it -- "When and under what circumstances Alphatec 09
- first became aware of each of the patents-in-suit 10
- and what actions Alphatec took upon becoming aware
- 12 of the patents-in-suit."
- 13 Did I read that correctly?
- 14 Α. Yes.
- 15 Do you understand that you have been
- 16 designated by Alphatec to provide Alphatec's
- 17 knowledge with respect to that topic?

4. PAGE 26:21 TO 27:08 (RUNNING 00:00:54.943)

- THE WITNESS: Yes.
- 22 BY MS. DEVINE:
- 23 Q. What can you tell me about Topic 2?
- 24 There were -- as part of our development Α.
- procedure, we requested from our legal department 25
- 00027:01 an evaluation of the IP landscape. I know that
 - 02 there were -- there were several patents, and I
 - 0.3
 - believe they are listed in a document here
 - 04 somewhere, that were in possession of our legal
 - 05 department.
 - 06 As far as what actions took place by
 - 07 Alphatec, that would have been within our legal
 - 0.8 department.

5. PAGE 27:09 TO 27:12 (RUNNING 00:00:09.083)

- 09 When you say as part of your development
- 10 procedure you requested an evaluation of the IP
- 11 landscape, at what point during the development
- procedure was the request made? 12

6. PAGE 27:20 TO 27:20 (RUNNING 00:00:02.180)

20 Ο. My only question is what date?

7. PAGE 27:23 TO 28:07 (RUNNING 00:00:36.212)

- 23 THE WITNESS: It was early 2013. The --
- and it is -- I believe your question was at what



```
NuVasive v. Alphatec - Video
             part during the development?
  00028:01
             BY MS. DEVINE:
        0.2
                  Q.
        03
                  Α.
                       It is early in the development.
        04
             basically, when concepts are first established,
        05
             once a product has enough of a form to have
        06
             features that can be evaluated, we initiate a
        07
             conversation to evaluate existing IP.
8. PAGE 33:01 TO 33:04 (RUNNING 00:00:09.332)
  00033:01
                   Ο.
                        So you said that request to legal to
        02
              evaluate the IP landscape was made in early 2013;
        03
             is that right?
                        To the best of my knowledge.
        04
                   Α.
9. PAGE 58:11 TO 58:15 (RUNNING 00:00:15.159)
                      So can you tell me, during the
             development of the Battalion products, which job
        13
             title you held?
        14
                   Α.
                        I believe I was a senior design engineer
        15
             and then a project engineer.
10. PAGE 218:09 TO 218:10 (RUNNING 00:00:08.291)
                        So I'm asking did Alphatec actually adopt
        10
              features of XLIF in developing Battalion?
11. PAGE 218:12 TO 218:24 (RUNNING 00:00:47.583)
                        THE WITNESS: I think, as you've stated,
        13
              I mean, they share some similar-looking features.
             You know, a shim. Now you've mentioned a, you
        14
             know, a generally three-blade -- three primary
        16
             blades with an optional fourth blade. There are
        17
             probably other similarities that I don't want to
        18
             guess at what else be the same. I haven't -- I'm
        19
             not familiar enough with the Nuvasive system to be
```

- 20 able to answer.
- 21 BY MS. DEVINE:
- 22 Q. Did Alphatec adopt those directly from
- 23 XLIF, or is it just happenstance that there are
- 24 similarities?

12. PAGE 219:01 TO 219:13 (RUNNING 00:00:47.594)

00219:01	THE WITNESS: I think kind of as
02	previously stated, I mean, I we ended up going
03	with a three-blade design because that's what we
04	got the most feedback on from the you know, what
05	at the time was an undeveloped team. But later on
06	we had a surgeon team that had the most to say
07	about a three-blade retractor.
08	BY MS. DEVINE:
09	Q. Did the original idea of trying a
10	three-bladed retractor come from Nuvasive's XLIF?
11	A. I wouldn't be able to say where its
12	origins were. There were multiple three-blade
13	retractor systems on the market at that time.

13. PAGE 228:07 TO 228:12 (RUNNING 00:00:22.229)

The court reporter has handed you a 0.8 document marked Robinson Exhibit 12, which is Bates 09 numbered ATEC LLIF 000137018 to 137039. And, 10 Mr. Robinson, take your time, and my question is 11 just going to be: 12 Do you recognize this documents?



NuVasive v. Alphatec - Video

14. PAGE 228:13 TO 229:02 (RUNNING 00:01:01.658)

```
13
                     I believe I do recognize this document,
                Α.
      14
          yes.
      15
                     Okay. What is it?
                     It's a business case presentation that
     16
                Α.
      17
           was very likely given to our leadership team.
      18
           date on the cover would tell me that we had a
      19
           business project management office that would have
           been making decisions on what products to -- what
      20
      2.1
           products were in product development they were
      2.2
           going to continue funding and which ones they were
      23
           not going to continue funding. So either Bryan or
      24
           Jon would have given this presentation to a group
      25
           of mostly executive level Alphatec employees to
00229:01
           make a case to continue working on our lateral
      02
           program.
```

15. PAGE 229:07 TO 229:22 (RUNNING 00:01:00.884)

```
If you turn to Page 137020, which is
     Page 3 of the presentation, do you see the two
08
     graphics of the patient positioning on that page?
09
1 0
               Yes, I do.
               Do you know where those are from?
11
          Ο.
12
          Α.
               I don't. I mean, I see images like that
     all the time. Just fairly generic patient
13
    positioning images.
15
          Q. Would it surprise you to know that come
16
     from Nuvasive literature?
17
         A. I don't know if surprise is the word. I
18
     guess it depends on the scope of the Nuvasive
19
     literature.
20
          Q.
               What do you mean?
21
          Α.
               I think by this point Nuvasive had
     published a book about lateral surgery.
```

16. PAGE 229:23 TO 229:24 (RUNNING 00:00:05.703)

Q. Can you turn to the seventh page of the PowerPoint, which is Bates labeled 137024. Do you

17. PAGE 229:25 TO 230:19 (RUNNING 00:00:39.827)

```
see that there appears to be a slide on top of a
      25
00230:01
           slide?
      02
      03
                     Do you know why that is?
                Q.
                Α.
                     I don't.
      05
                     Do you see that the slide on top the
                Q.
      06
           slide states: "Massive OUS potential"?
      07
                Α.
                     Yes.
      0.8
                Q.
                     And underneath that, there's some header
      09
           that says, "Develop and expand across Latin
      10
           America."
      11
                     Do you see that?
      12
                Α.
                     Yes, I do.
      13
                     And three bullet points down it says,
                Ο.
           "Currently in nine countries."
     14
      15
                     Do you see that?
      16
                Α.
                     Yes.
      17
                Ο.
                     Was Alphatec currently in nine countries
           with the lateral procedure as of the date of this
      18
      19
           presentation, June 2014?
```

18. PAGE 230:21 TO 231:13 (RUNNING 00:00:38.711)

THE WITNESS: Not to my knowledge.
BY MS. DEVINE:



NuVasive v. Alphatec - Video

```
23
                   So do you know what that references?
               Ο.
      24
                   I -- what "currently in nine
               Α.
          countries" --
      25
00231:01
                O. Mm-hmm.
      02
                Α.
                     -- references?
      03
                    Mm-hmm.
                Q.
      04
               Α.
                    No, I don't know any specifics about
      05
           that, no.
                     Do you think it could be Nuvasive?
      06
               Q.
      07
                    I believe that's a possibility.
                Α.
      0.8
                Q.
                   Are you aware that Nuvasive tends to
          market with purple?
      09
     10
                Α.
                     I am aware, yes.
     11
                Q.
                     And this slide within a slide here is
     12
           colored with Nuvasive purple, correct?
     13
                     Close enough, yes.
```

19. PAGE 231:14 TO 231:15 (RUNNING 00:00:07.285)

14 Q. Does Alphatec regularly present to 15 management with information about Nuvasive?

20. PAGE 231:17 TO 231:21 (RUNNING 00:00:19.576)

```
17 THE WITNESS: I'm not sure where that
18 slide came from. I would say that generally any
19 company has some idea of what the competition is up
20 to just as a case to be aware of the landscape in
21 which we're doing business.
```

21. PAGE 232:08 TO 233:04 (RUNNING 00:00:38.820)

```
So Page 10, which is Bates labeled
                Ο.
           137027.
      09
                    Are you on that page?
      10
                Α.
                     Yes.
      11
                     And it states: "What is the project
                Ο.
      12
           scope?"
      13
                     Do you see that?
      14
                Α.
                     And it states: "Retractor system."
      15
                Q.
      16
                     Do you see that?
      17
                A.
                     Yes.
      18
                     And it states: "Access system
                Q.
           specifically designed to create a safe reproducible
      19
      2.0
           surgical pathway."
      21
                     Do you see that?
      22
                     I do, yes.
      23
                Q.
                     Are you aware that Nuvasive markets its
      2.4
           XLIF system as a safe reproducible system?
      25
                Α.
                     Only generally, no specifics.
                     What retractor is pictured here?
00233:01
                Q.
      02
                     I believe that's a MAS retractor.
                Α.
      03
                     Which is the Nuvasive retractor, correct?
                Ο.
      04
                     It's the Nuvasive retractor.
                Α.
```

22. PAGE 233:05 TO 233:11 (RUNNING 00:00:33.877)

Q. So this team of Bryan Larsen and Jon
Costabile was presenting to management the project
scope of LLIF with a picture of the Nuvasive MAS
retractor, correct?

A. Without knowing to what end they wanted
an image on the slide, they were showing an image
of a MAS retractor during a management update.

23. PAGE 233:21 TO 234:02 (RUNNING 00:00:17.417)

Q. But this particular slide is about a retractor system, correct?



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

